Palmoplantar Psoriasis Resistant to Adalimumab Successfully Treated with Bimekizumab.

Dermatol Pract Concept

Unit of Dermatology, Department of Medical, Surgical and Neurosciences, University of Siena, Siena, Italy.

Published: October 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619968PMC
http://dx.doi.org/10.5826/dpc.1404a244DOI Listing

Publication Analysis

Top Keywords

palmoplantar psoriasis
4
psoriasis resistant
4
resistant adalimumab
4
adalimumab treated
4
treated bimekizumab
4
palmoplantar
1
resistant
1
adalimumab
1
treated
1
bimekizumab
1

Similar Publications

Background: Narrowband-ultraviolet B (NB-UVB) phototherapy is an effective treatment for psoriasis in patients who have failed topical regimens or those who desire to avoid systemic treatment. Despite its regular use in non-white individuals, NB-UVB treatment response for psoriasis in skin of color (SOC) has not been systematically reviewed.

Methods: We conducted a systematic review on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) on all available studies to date assessing NB-UVB for psoriasis treatment in skin of color (SOC) (up to 15 November 2024).

View Article and Find Full Text PDF

Background: Ethnic differences in the clinical and molecular features of many immune-mediated dermatoses have been reported, including psoriasis vulgaris and generalized pustular psoriasis. Palmoplantar pustulosis (PPP) is a chronic and relapsing inflammatory skin disease manifesting as crops of sterile pustules over an erythematous base on the palms and soles. To date, ethnic differences in PPP have been rarely studied.

View Article and Find Full Text PDF

Palmoplantar psoriasis is a rare, chronic, localized variant of psoriasis. It represents 3-4% of all psoriasis cases and is characterized by hyperkeratotic or desquamative erythematous plaques with fissures and erosions exhibiting acral distribution. Occasionally, superimposed sterile pustulations may also occur.

View Article and Find Full Text PDF

Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis.

Psoriasis (Auckl)

August 2025

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Psoriasis is an immune-mediated chronic inflammatory skin disease affecting over 60 million adults and children worldwide and can occur at any age, from childhood to adulthood. If the patient has a diffuse form of psoriasis, affecting more than ten percent of the body surface, or involving sensitive areas such as the face, scalp, nails, and/or palmoplantar region, he or she is a candidate for systemic therapy. Currently, several drugs are approved for the treatment of moderate to severe chronic plaque psoriasis in Europe and US.

View Article and Find Full Text PDF